Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMOMLHJ)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Aureociclin; Aureomicina; Aurofac; Biovetin; Centraureo; Chlortetracyclin; Chrusomykine; Limeciclina; Lymecyclinum; Orospray; Acronize PD; Aurofac 10; Tetrlysal 300; Lymecycline (INN); Tetralysal 300 (TN); N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
| |||||
| Therapeutic Class | Antibiotics | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||
|
|||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||
